At a Glance
Therapeutic Area:
Rheumatoid Arthritis, Crohn's Disease
Approved Applications:
An anti-TNF biologic which has been approved for the treatment of Crohn's disease in the United States and for the treatment of rheumatoid arthritis in the United States and in the European Union. Cimzia blocks the action of tumor necrosis factor-alpha, a protein that plays a role in causing inflammation in rheumatoid arthritis.
Applications In Development:
Psoriatic Arthritis
Acquisition Date:
February 2011
Royalty Seller:


"This transaction demonstrates our ability to unlock unrecognized value in Nektar's legacy collaborations and access significant capital in a non-dilutive transaction. The proceeds from this sale will strengthen our cash position considerably and we are pleased to have Royalty Pharma as our partner in this transaction."

Howard W. Robin, President and Chief Executive Officer of Nektar Therapeutics
© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.